Rhythm Pharmaceuticals revealed that CEO David Meeker and CFO Hunter Smith will participate in fireside chats at major investor conferences in Boston and New York during August and September 2026. These events provide the company an opportunity to discuss its commercial-stage biopharmaceutical developments, including its lead product IMCIVREE® for rare neuroendocrine diseases. The sessions will be webcast and available on Rhythm's website, allowing investors to gain insights into the company's progress and future plans. This engagement highlights Rhythm's efforts to maintain transparency and investor relations as it advances its clinical programs and market presence.
Alkermes plc's drug ALKS7290 demonstrated significant improvement in ADHD symptoms in a Phase 1b trial, with patients showing a 14- to 19-point gain on a 54-point scale within two weeks. This outperforms typical placebo effects, which range from 6 to...
Morgan Stanley upgraded NNN REIT from Neutral to Overweight due to its stable income and strong financial health. The REIT boasts a 99.1% occupancy rate and 97.5% fixed-rate debt, ensuring steady rental income and protection against interest rate hik...
Coinbase has launched a new feature allowing eligible U.S. retail traders to request IPO shares at the offer price before public trading begins, starting with Oura's IPO. This move gives retail investors early access to high-interest companies and en...
World Liberty Financial has launched a governance vote proposing a new rewards program for WLFI token holders. To earn rewards, holders must lock their tokens for 180 days and actively vote on governance proposals at least once every 90 days, with de...
Bitcoin's price approached $86,000, its highest level in eight months, marking a 6% increase in 24 hours and over 30% since August 19. Despite this rise, US spot demand remains weak as indicated by the slightly negative Coinbase premium, suggesting l...
